Alkaline phosphatase · children with X‐linked hypophosphataemia
1 finding from 1 review
Measures of renal function: change in TmP/GFR · children with X‐linked hypophosphataemia
It is very uncertain whether summary of findings ‐ recombinant growth hormone changes measures of renal function: change in TmP/GFR compared with placebo or no intervention (very low certainty).
1 finding from 1 review
Body proportions: sitting height SDS · children with X‐linked hypophosphataemia
Summary of findings ‐ recombinant growth hormone showed no clear difference in body proportions: sitting height SDS compared with placebo or no intervention (moderate certainty).
1 finding from 1 review
Adverse effects · children with X‐linked hypophosphataemia
1 finding from 1 review
Depressive symptomology (continuous) HDRS where possible; higher scores indicate greater symptomology · adults with Major Depressive Disorder
1 finding from 1 review
Adverse events Study reports · adults with Major Depressive Disorder
It is very uncertain whether n3PUFAs changes adverse eventsStudy reports compared with placebo (very low certainty).
1 finding from 1 review
Depressive symptomology (dichotomous ‐ remission) Depressive symptomology rating scale as used by authors · adults with Major Depressive Disorder
n3PUFAs showed no clear difference in depressive symptomology (dichotomous ‐ remission)Depressive… compared with placebo (low certainty).
1 finding from 1 review
Depressive symptomology (dichotomous ‐ response) Depressive symptomology rating scale as used by authors · adults with Major Depressive Disorder
n3PUFAs showed no clear difference in depressive symptomology (dichotomous ‐ response)Depressive… compared with placebo (low certainty).
1 finding from 1 review
Quality of lifeValidated quality of life scales as used by authors, CGI (7‐point scale) where possible, higher scores indicate poorer quality of life · adults with Major Depressive Disorder
1 finding from 1 review
Trial non‐completionStudy reports · adults with Major Depressive Disorder
It is very uncertain whether n3PUFAs changes trial non‐completionStudy reports compared with placebo (very low certainty).
1 finding from 1 review
Pain ‐ not reported · acute gout
The review found no eligible studies for this question.
1 finding from 1 review
Proportion with 50% or greater decrease in inflammation score from baseline ‐ 32 to 36 hours · acute gout
High‐dose colchicine may leads to higher reduction of inflammation: proportion with 50% or greater decrease… compared with placebo (low certainty).
1 finding from 1 review
Function of target joint ‐ not measured · acute gout
The review found no eligible studies for this question.
1 finding from 1 review
Serious adverse events · acute gout
1 finding from 1 review
Total adverse events · acute gout
High‐dose colchicine may leads to higher total adverse events compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · acute gout
1 finding from 1 review
Participant global assessment of treatment success: proportion with 50% or greater decrease in pain score from baseline ‐ 32 to 36 hours · acute gout
Low‐dose colchicine may leads to higher participant global assessment of treatment success: proportion with… compared with placebo (low certainty).
1 finding from 1 review
Reduction of inflammation ‐ not measured · acute gout
The review found no eligible studies for this question.
1 finding from 1 review
Function of target joint ‐ not measured · acute gout
The review found no eligible studies for this question.
1 finding from 1 review
Serious adverse events · acute gout
1 finding from 1 review